Skip to main content
Premium Trial:

Request an Annual Quote

Compugen Releases New Version of 2-D Gel Analysis Tool

NEW YORK, Feb 1 – Compugen has released a new version of its Z3 high-throughput two dimensional gel electrophoresis analysis system for proteins, the company announced Thursday.

This system, which the company initially introduced in September, automates the process of analyzing 2D gel separations of complex proteins using proprietary algorithms for gel comparison. Using a color overlay technology, it allows comparison of protein expression in normal and diseased tissues.

" In addition to significantly reducing the analysis time, the new version also introduces a unique feature which allows extracting comprehensive and accurate information from repeated experiments," Amit Rubinfeld, Compugen's Z3 Product Manager, said in a statement.

In the new version, users can create one image from several gels of the same sample, a protein annotation feature, and prediction algorithms for the PI and mass of protein components. The new version also supports Windows 2000, Windows 98, and NT 4.0.

The company charges $29,000 per one-year license, but add-on features are extra.

Compugen’s customers for its Z3 system include the Australian Proteome Analysis Facility, Aventis Pharma, Genentech, NV Organon, Pfizer, Procter & Gamble, [email protected], and Proteologics.

The Scan

Unwrapping Mummies' Faces

LiveScience reports that Parabon NanoLabs researchers have reconstructed how three Egyptian mummies may have looked.

Study on Hold

The Spectrum 10K study has been put on hold due to a backlash, leading the researchers to conduct consultations with the autism community, Nature News reports.

Others Out There Already

Reuters reports that Sanofi is no longer developing an mRNA-based vaccine for SARS-CoV-2.

PNAS Papers on GWAS False Discovery, PRAMEF2 Role in Tumorigenesis, RNA Virus Reverse Genetics

In PNAS this week: strategy to account for GWAS false-discovery rates, role of PRAMEF2 in cancer development, and more.